← Eichor
Study identifier: NCT06945861 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Immunological Aspect of Thrombotic Thrombocytopenic Purpura (TTP)

Condition: Thrombotic Thrombocytopenic Purpura (TTP)  ·  Sponsor: University Hospital, Rouen

PhaseN/A
Planned participants44
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The general objective of the proposed project is to characterise phenotypically and functionally ADAMTS13-specific memory B lymphocytes and autoreactive T lymphocytes, in particular follicular helper T lymphocytes, in the acute phase of the disease, but also during its progression after treatment. The aim is to highlight their contribution to the initial pathogenic process, their evolution under treatment, and also their involvement in patients who are refractory to immunosuppressive therapies and during relapses. The aim of this project is to identify early phenotypic or functional parameters that are predictive of relapse and that can be used for personalised optimisation of treatment to maintain remission.

This description comes directly from the study's public registry record.

Talk to the study team

David DM MALLET, Director  ·  02 32 88 82 65  ·  david.mallet@chu-rouen.fr

Vincent VF FERRANTI, ARC  ·  02 32 88 82 65  ·  vincent.ferranti@chu-rouen.fr

Always discuss trial participation with your own doctor first.

Locations (1)

University Rouen Hospital,Rouen, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06945861